Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards

作者：Scott R. Evans, Thomas R. Fleming, Holly Janes, Lori E. Dodd · 发表于：JAMA · 年份：2026 · DOI：10.1001/jama.2026.4175 · 被引用次数：3 · 研究领域：Statistical Methods in Clinical Trials、Meta-analysis and systematic reviews、Ethics in Clinical Research

This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.